Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32 (DHX32)
- Target
- DHX32
- Molecular classification
- Enzyme (RNA helicase), DEAH-box helicase family, RNA-binding protein, Spliceosomal protein (putative)
01
Overview
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32 (DHX32) is an RNA helicase belonging to the DEAH-box family, characterized by unique structural motifs and partially conserved helicase domains. It is widely expressed in human tissues and localized to both the nucleus and mitochondria, indicating a diversity of functions. DHX32 participates in key processes of RNA metabolism, including ribosome biosynthesis, transcription, splicing, and translation. Dysregulated DHX32 expression is associated with several cancers, being upregulated in solid tumors such as colorectal and breast cancer and downregulated in some leukemias. This association highlights its potential as a diagnostic and prognostic biomarker as well as a putative therapeutic target, though no drugs currently target DHX32 directly. Further research is needed to clarify its precise functional impact in cancer and other diseases.
- Other names
- DDX32DHLP1DEAD/H box 32DEAD/H helicase-like protein 1DEAH box protein 32DEAH (Asp-Glu-Ala-His) box polypeptide 32HuDDX32Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32FLJ10889FLJ10694
02
Mechanism of action
No drugs directly targeting DHX32 documented; mechanism would likely involve modulation of RNA helicase activity or intervention in RNA metabolism and splicing pathways if a drug were developed
03
Biological functions
Ribosome biosynthesismRNA transcriptionmRNA splicingTranslationGene expression regulationCell proliferationCell differentiationApoptosisMitochondrial gene expression regulationPost-transcriptional modification (alternative splicing)
04
Disease associations
Cancer (upregulated in solid tumors: colorectal and breast cancer)Hematological malignancies (downregulated in acute lymphoblastic leukemia, role in lymphoma and leukemia prognosis)Chemotherapy resistance in leukemiaOther: Combined oxidative phosphorylation deficiency 8
05
Safety considerations
Potential challenges due to widespread expression in normal tissuesPossible off-target effects impacting essential RNA metabolism or gene expressionSpecific safety concerns are not documented due to absence of clinical therapeutics
06
Biomarkers
Potential biomarker for tumor diagnosis and prognosis in lymphoma, leukemia, colorectal cancer, and breast cancer (expression levels correlate with malignancy and resistance)
Beyond the preview
Go deeper on Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32 (DHX32).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX32 (DHX32).